RNA Therapeutics Market Report Size, Research Analysis, Industry Share, Growth, Opportunities, Business Overview, Forecast to 2028
In February 2023, Moderna, Inc. received authorization from Health Canada for its COVID-19 booster vaccine, mRNA-1273.214 (SpikevaxBivalent Original/Omicron). This vaccine is designed for immunization against COVID-19 in children and adolescents between 6 to 17 years.
View full press release